drugset / Trial / NCT06528249
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
Phase 1
Not yet recruiting
39 enrolled
Zhejiang Provincial People's Hospital
Westlake Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an investigator-initiated, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Erythrocyte-αPD-1 conjugates in patients with advanced malignancies
Timeline
- Start
- 2024-07-31
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erythrocyte-αPD-1 conjugate | Cell therapy | — | — |